JP Morgan Chase’s Arena Pharmaceuticals Inc ARNA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q3 | – | Sell |
-35,000
| Closed | -$2.2M | – | 5933 |
|
|
2020
Q2 | $2.2M | Buy |
+35,000
| New | +$1.93M | ﹤0.01% | 3044 |
|
|
2019
Q2 | – | Sell |
-30,000
| Closed | -$1.34M | – | 6111 |
|
|
2019
Q1 | $1.34M | Sell |
30,000
-5,000
| -14% | -$229K | ﹤0.01% | 3612 |
|
|
2018
Q4 | $1.36M | Hold |
35,000
| – | – | ﹤0.01% | 3553 |
|
|
2018
Q3 | $1.61M | Hold |
35,000
| – | – | ﹤0.01% | 3611 |
|
|
2018
Q2 | $1.53M | Sell |
35,000
-60,000
| -63% | -$2.58M | ﹤0.01% | 3594 |
|
|
2018
Q1 | $3.75M | Buy |
+95,000
| New | +$3.7M | ﹤0.01% | 2807 |
|
|
2015
Q1 | – | Sell |
-190
| Closed | -$7K | – | 4341 |
|
|
2014
Q4 | $7K | Sell |
190
-280
| -60% | -$11.4K | ﹤0.01% | 4195 |
|
|
2014
Q3 | $20K | Buy |
+470
| New | +$21K | ﹤0.01% | 4144 |
|
|
2014
Q1 | – | Sell |
-70
| Closed | -$4K | – | 4023 |
|
|
2013
Q4 | $4K | Hold |
70
| – | – | ﹤0.01% | 4059 |
|
|
2013
Q3 | $4K | Hold |
70
| – | – | ﹤0.01% | 4350 |
|
|
2013
Q2 | $5K | Buy |
+70
| New | +$5.71K | ﹤0.01% | 4353 |
|
JP Morgan Chase's ARNA Position: Q1 2022 in Review
JP Morgan Chase sold out of Arena Pharmaceuticals Inc (ARNA) in Q1 2022, closing a stake of 845,595 shares — an estimated $78.6M sold.
JP Morgan Chase first reported a position in ARNA in Q2 2013 and held it in 24 quarters. The position peaked at $78.6M in Q4 2021. 1 fund tracked by Wall St. Rank holds ARNA as of Q1 2022.
- JP Morgan Chase reported no remaining Arena Pharmaceuticals Inc position as of Q1 2022 after selling out during the quarter.
- JP Morgan Chase sold 845,595 Arena Pharmaceuticals Inc shares in Q1 2022, an estimated $78.6M.
- JP Morgan Chase first reported a position in Arena Pharmaceuticals Inc in Q2 2013 and held it in 24 quarters.
- JP Morgan Chase's Arena Pharmaceuticals Inc position peaked at $78.6M in Q4 2021.
- 1 fund tracked by Wall St. Rank held Arena Pharmaceuticals Inc as of Q1 2022.
Based on JP Morgan Chase's 13F filing for Q1 2022, filed 11 May 2022.